Recurrence | Death | |||||||
---|---|---|---|---|---|---|---|---|
Uni-variate analysis | Multi-variate analysis | Uni-variate analysis | Multi-variate analysis | |||||
HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
Male sex | 0.855 (0.406–1.799) | 0.680 | 0.846 (0.421–1.702) | 0.639 | ||||
Age, years | 0.980 (0.952–1.009) | 0.175 | 1.037 (1.005–1.069) | 0.022 | 1.047 (1.000–1.096) | 0.044 | ||
ASA 3–4 | 0.381 (0.082–1.760) | 0.216 | 0.186 (0.022–1.586) | 0.124 | 0.690 (0.210–2.265) | 0.541 | ||
Preoperative serum CEA, ng/ml | 1.029 (1.004–1.054) | 0.020 | 1.024 (0.995–1.053) | 0.101 | 1.035 (1.009–1.061) | 0.009 | 1.027 (0.991–1.063) | 0.142 |
Interval from SEMS to resection, days | 0.977 (0.939–1.017) | 0.252 | 1.012 (0.978–1.047) | 0.492 | ||||
Stoma directly after resection | 2.879 (0.967–8.573) | 0.057 | 5.189 (1.662–16.202) | 0.005 | 6.617 (1.287–34.009) | 0.024 | ||
Adjuvant chemotherapy | 0.579 (0.248–1.351) | 0.579 | 0.404 (0.149–1.094) | 0.075 | 0.218 (0.096–0.496) | <0.001 | 0.151 (0.044–0.515) | 0.003 |
Overall pathologic stage III | 4.183 (1.761–9.935) | 0.001 | 2.888 (1.365–6.107) | 0.006 | 5.243 (1.548–17.757) | 0.008 | ||
PD/Mucinous cancer | 4.629 (0.743–28.835) | 0.101 | 9.302 (1.010–85.672) | 0.049 | 9.835 (0.770–125.638) | 0.079 | ||
Metastatic LN, n | 1.385 (1.172–1.636) | <0.001 | 1.387 (1.155–1.666) | <0.001 | 1.172 (1.046–1.313) | 0.006 | 1.185 (1.004–1.400) | 0.045 |
Lymphovascular invasion | 2.337 (1.058–5.161) | 0.036 | 1.054 (0.699–3.234) | 0.296 | ||||
Perineural invasion | 3.692 (1.426–9.559) | 0.007 | 1.027 (0.495–2.131) | 0.942 | 0.271 (0.093–0.790) | 0.017 |